Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00508547
Recruitment Status : Recruiting
First Posted : July 30, 2007
Last Update Posted : September 29, 2021
Sponsor:
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC

Brief Summary:
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.

Condition or disease
Psoriasis

Detailed Description:
PSOLAR is an ongoing voluntary observational study in which infliximab-exposed patients, ustekinumab-exposed patients, and patients treated with other biologic and non-biologic standard of care therapies have been enrolled internationally and are followed for up to 8 years. Additionally, enrollment is opened to include at least 2000 guselkumab-exposed patients and up to 2000 patients exposed to IL-17 inhibitors. The Registry does not require any study-specific testing, but may capture information collected as part of normal routine care. Patient information is collected at the enrollment visit and about every 6 months thereafter. At enrollment, information on demographics (e.g. gender, and race), medical history and family medical history, details of past and current psoriasis treatments, and current psoriasis medications is collected. At enrollment and each follow-up visit, data are collected regarding physical examination, clinical disease status, Quality of Life assessments, current psoriasis medications, patient-reported PsA assessments, and adverse events. No study agents are administered for the purpose of this registry; all patients receive standard of care treatment as prescribed by the patient's physician.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 16000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 8 Years
Official Title: A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Actual Study Start Date : June 21, 2007
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : December 31, 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Group/Cohort
Guselkumab
Participants will receive guselkumab as prescribed by the physician according to standard of care for psoriasis.
Infliximab
Participants will receive infliximab as prescribed by the physician according to standard of care for psoriasis.
Ustekinumab
Participants will receive ustekinumab as prescribed by the physician according to standard of care for psoriasis.
Biological Therapies
Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
Conventional Systemic Agents
Participants will receive conventional systemic agents as prescribed by the physician for psoriasis. Participants will not receive any intervention as a part of this study.
IL-17 Inhibitor
Participants will receive an IL-17 inhibitor as prescribed by the physician according to standard of care for psoriasis.



Primary Outcome Measures :
  1. Adverse Events and Serious Adverse Events [ Time Frame: Up to 8 years of follow up for each patient ]
    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; suspected transmission of any infectious agent via medicinal product; or any important medical events. All adverse events, including those of special interest, such as malignancies; TB; opportunistic infections; depression; hypersensitivity reactions; autoimmune disease; neurologic or demyelinating events; congestive heart failure; hepatotoxicity; hematologic events; unexpected reaction to a vaccine; cerebrovascular accident; transient ischemic attack; confirmed myocardial infarction; and acquired immunodeficiency syndrome will be documented.


Secondary Outcome Measures :
  1. Evaluation of disease features: Physicians global assessment of disease activity (PGA) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
  2. Evaluation of Disease Features: Body surface area [ Time Frame: At baseline and every 6 months through up to 8 years ]
  3. Evaluation of Disease Features: Psoriasis Area and Severity Index (PASI) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
  4. Dermatology Life Quality Index (DLQI) Score [ Time Frame: At baseline and every 6 months through up to 8 years ]
  5. EuroQOL quality of life assessment [ Time Frame: At baseline and every 6 months through up to 8 years ]
  6. Hospital Anxiety and Depression Scale (HADS) Score [ Time Frame: At baseline and every 6 months up to Month 18 and then every year up to 8 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient with psoriasis who meets the inclusion criteria will be eligible to participate in this registry.
Criteria

Inclusion Criteria:

  • Have a diagnosis of psoriasis
  • Are currently taking Tremfya or an Interleukin-17 (IL-17) inhibitor (example, secukinumab, ixekizumab, brodalumab) or will be initiating treatment with Tremfya or an IL-17 inhibitor at the time of their enrollment. Patients who completed prior participation in PSOLAR may re-enroll as long as they are receiving or initiating treatment with Tremfya or an IL-17 inhibitor
  • Ability to understand and sign an informed consent form
  • Are willing to participate in regular follow-up visits

Exclusion Criteria:

  • Refuse to consent or are unwilling to respond to request for a long term information within the required time frame
  • Are participating or have already planned to participate in a clinical trial with non-marketed investigational agents or are participating in a Janssen-sponsored clinical trial with marketed agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508547


Contacts
Layout table for location contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

Locations
Show Show 444 study locations
Sponsors and Collaborators
Janssen Scientific Affairs, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Scientific Affairs, LLC Clinical Trial Janssen Scientific Affairs, LLC
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier: NCT00508547    
Other Study ID Numbers: CR013225
PSOLAR ( Other Identifier: Janssen Scientific Affairs, LLC )
First Posted: July 30, 2007    Key Record Dates
Last Update Posted: September 29, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Janssen Scientific Affairs, LLC:
psoriasis
psoriatic arthritis
skin disease
infliximab
ustekinumab
guselkumab
etanercept
adalimumab
secukinumab
ixekizumab
brodalumab
systemic therapy
observational
registry
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases